EMEA-002141-PIP01-17-M02
Key facts
| Active substance |
Crizanlizumab
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0379/2019
|
| PIP number |
EMEA-002141-PIP01-17-M02
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of sickle cell disease
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|